Judge squashes Mylan's "unripe" suit urging FDA to rule on Ranbaxy's generic Lipitor
This article was originally published in Scrip
Executive Summary
A federal judge has thrown out Mylan's lawsuit which sought to compel the US FDA to "immediately decide" and "make public" its position on the status of Ranbaxy's ANDA and whether or not Ranbaxy will be granted an exclusive six-month exclusivity period to sell its version of Pfizer's Lipitor (atorvastatin).